

# Axinn Successfully Represents Alvogen Before FTC

NEWS | LESS THAN 1 MIN READ


November 3, 2015

Axinn successfully represented Alvogen before the Federal Trade Commission in connection with Alvogen's approval to buy the divestiture products in the proposed Mylan/Perrigo transaction. Mylan's bid for Perrigo is valued at \$25 billion, and Alvogen will acquire seven separate pharmaceutical products as a result of the FTC-mandated and approved divestiture. Alvogen was also approved to acquire the divestiture products in Pfizer/Hospira earlier this year. The FTC's Mylan press release can be found [here](#).


The Axinn team based in Washington, DC consisted of partner Michael Keeley, assisted by associate Kenina Lee.

## Related People

---



Michael L. Keeley



Kenina J. Lee

## Related Services

---

Antitrust

To subscribe to our publications, [click here](#).

## Featured Insights

- GCR Live: Law Leaders Europe 2025  
**SPEAKING ENGAGEMENT    ANTITRUST**
- AHLA Annual Meeting 2025  
**SPEAKING ENGAGEMENT    ANTITRUST**
- SABA North America Annual Conference 2025  
**SPEAKING ENGAGEMENT    ANTITRUST**
- Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses  
**WEBINAR    ANTITRUST**
- Volunteer Lawyers for the Arts – Champions of the Arts Awards and Gala 2025  
**SPONSORSHIP    ANTITRUST**
- NJSBA Annual Meeting and Convention 2025  
**SPEAKING ENGAGEMENT    INTELLECTUAL PROPERTY**
- Cost-Effective and Efficient IP Litigation Strategies – Making Paragraph IV Litigation Work for You  
**WEBINAR    INTELLECTUAL PROPERTY**

- Hartford HealthCare Black and Red Gala 2025  
SPONSORSHIP      ANTITRUST
- Informa CompLaw Antitrust West Coast Conference 2025  
SPEAKING ENGAGEMENT      ANTITRUST
- Recent Decision Shows the Heavy Burden of Actual Malice in Defamation Suits  
AXINN VIEWPOINTS      LITIGATION & TRIALS